Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era

Cancer

Volumn 118, Issue 14, 2012, Pages 3571-3578

  Turley, Ryan S ^a   Peng, Peter D ^b   Reddy, Srinevas K ^c   Barbas, Andrew S ^a   Geller, David A ^c   Marsh, J Wallis ^c   Tsung, Allan ^c   Pawlik, Timothy M ^b   Clary, Bryan M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

gastrointestinal stromal tumor; hepatectomy; imatinib; liver resection; tyrosine kinase inhibitor

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

ADULT; AGED; ARTICLE; BILE LEAKAGE; BILOMA; BLEEDING; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; EMPYEMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HEART ATRIUM FIBRILLATION; HEMIHEPATECTOMY; HEPATORENAL SYNDROME; HUMAN; LIVER FAILURE; LIVER METASTASIS; LIVER RESECTION; MALE; METASTASIS RESECTION; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PULMONARY ASPIRATION; RESPIRATORY FAILURE; SUBPHRENIC ABSCESS; SURGICAL TECHNIQUE; SURVIVAL RATE; SYSTEMIC THERAPY; TREATMENT OUTCOME; WOUND DEHISCENCE; WOUND INFECTION;

AGED; COMBINED MODALITY THERAPY; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84863320663     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26650     Document Type: Article

References (31)

1. Nishida T, Hirota S,. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol. 2000; 15: 1293-1301.
2. Lewis JJ, Brennan MF,. Soft tissue sarcomas. Curr Probl Surg. 1996; 33: 817-872.
3. Katz SC, DeMatteo RP,. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol. 2008; 97: 350-359. (Pubitemid 351358583)
4. Zalinski S, Palavecino M, Abdalla EK,. Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin North Am. 2009; 23: 115-127, ix.
5. Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF,. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol. 2001; 8: 290-299. (Pubitemid 32422853)
6. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF,. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg. 2001; 234: 540-547; discussion 547-548.
7. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA,. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg; 2006; 141: 537-543; discussion 543-544.
8. Nunobe S, Sano T, Shimada K, Sakamoto Y, Kosuge T,. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn J Clin Oncol. 2005; 35: 338-341. (Pubitemid 41444282)
9. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-480. (Pubitemid 34879334)
10. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279: 577-580. (Pubitemid 28067289)
11. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC,. KIT mutations are common in incidental gastrointestinal stromal tumors 1 centimeter or less in size. Am J Pathol. 2002; 160: 1567-1572. (Pubitemid 34525636)
12. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR,. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007; 245: 347-352. (Pubitemid 46673128)
13. Steeghs N, Nortier JW, Gelderblom H,. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Annals of Surg Oncol. 2007; 14 (2): 942-953. (Pubitemid 46175346)
14. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg. 2003; 186: 665-669. (Pubitemid 37522103)
15. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005; 11: 4182-4190. (Pubitemid 40791584)
16. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004; 64: 5913-5919. (Pubitemid 39129383)
17. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21: 4342-4349. (Pubitemid 46621810)
18. Zhu J, Yang Y, Zhou L, Jiang M, Hou M,. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome [serial online]. BMC Cancer. 2010; 10: 199.
19. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 1097-1104.
20. Xia L, Zhang MM, Ji L, Li X, Wu XT,. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today. 2010; 40: 936-942.
21. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. Version 1.2011. Fort Washington, PA: NCCN; 2011.
22. Dindo D, Demartines N, Clavien PA,. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery. 2004; 240: 205-213. (Pubitemid 38963009)
23. Strasberg SM,; The International Hepato-Pancreato-Biliary Association Terminology Committee Survey. The Brisbane 2000 Terminology of Liver Anatomy and Resections. HBP (Oxf). 2000; 2: 333-339. (Pubitemid 32185922)
24. Reddy SK, AS Barbas, RS Turley, et al. A standard definition of major hepatectomy: resection of 4 or more liver segments. HPB (Oxf). 2011; 13: 494-501.
25. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
26. Cox D,. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
27. Gronnesby JK, Borgan O,. A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal. 1996; 2: 315-328. (Pubitemid 126415889)
28. Haller F, Detken S, Schulten HJ, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007; 14: 526-532. (Pubitemid 46175297)
29. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364: 1127-1134. (Pubitemid 39296599)
30. Chaudhry UI, DeMatteo RP,. Management of resectable gastrointestinal stromal tumor. Hematol Oncol Clin North Am. 2009; 23: 79-96, viii.
31. Babyak MA,. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med. 2004; 66: 411-421. (Pubitemid 38668414)